semaglutide tablets dosage for weight loss Dosing & Prescribing FDA Approves Oral Semaglutide: First

Neuropathy and vascular injury in diabetes compromise skin integrity and disrupt mucosal barriers, facilitating bacterial invasion (68, 69)

Tirzepatides cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing as of 2026

In people with T2D, SUSTAIN-6 revealed increased diabetic-retinopathy complications with semaglutide, primarily in subjects with pre-existing retinopathy and rapid HbA1c reduction 45,46

"This trial provides highly anticipated evidence for physicians and should bring real peace of mind to venous thrombosis patients, who often live with the dual fear of blood clot recurrence and bleeding," study leader Dr

Share your goals with those around you who can offer encouragement, and consider joining a weight-loss or wellness group for additional motivation

When formulations evolve and safety data changes, having a trusted resource that keeps pace matters